



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Board Change**

**London: Monday, 2 June 2008:** Chi-Med today announces that Mr Shigeru Endo has been appointed as a Non-executive Director of Chi-Med with effect from 1 June 2008.

Mr Endo, aged 73, worked for over 40 years with Mitsui, where he became senior executive managing director and a member of the main board of Mitsui and Company Ltd. He is chief executive officer and a director of Hutchison Whampoa Japan K.K., an executive director of Hutchison Harbour Ring Limited (a company listed on The Stock Exchange of Hong Kong Limited and a subsidiary of Hutchison Whampoa Limited), and a manager (equivalent to director in the UK) of Hutchison Europe Telecommunications S.à r.l. He is also a director of Axwood Developments Limited, Hutchison Whampoa Japan Limited, Infomart Corporation and PRD Electronics Limited and was a director of TRY Electronics Japan Ltd. from 2002 to 2006.

Mr Endo holds a Bachelor of Arts degree in Economics from Keio University. During his career, Mr Endo, a Japanese citizen and fluent English and Mandarin speaker, has managed large-scale business operations in Japan, China and the United States.

Save for the information disclosed above, there is no other information in relation to Mr Endo required to be disclosed pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Mr Simon To, Chairman said: "We very much welcome Mr Endo. His skills and experience will complement and strengthen Chi-Med's Board."

**Ends**

**Enquiries**

**Chi-Med**  
Christian Hogg, CEO

Telephone: +852 2121 8200

**Citigate Dewe Rogerson**  
Anthony Carlisle  
David Dible

Telephone: +44 (0) 20 7638 9571  
+44 (0) 7973 611 888  
+44 (0) 7967 566 919

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group focused on traditional Chinese medicine (“TCM”) based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med operates three core business divisions: 1) China Healthcare – the manufacture, distribution and marketing of pharmaceuticals and health supplements in China; 2) Drug R&D – the discovery and global development of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer Products – global retailing and distribution consumer health and personal care products derived from TCM and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.